Guggenheim Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $80

Guggenheim analyst Delma Caiati has initiated coverage on LB Pharmaceuticals (NASDAQ: LBRX) with a Buy rating. The firm has set a price target of $80 for the stock.